Thursday, October 15, 2026
ExploreSearch
Via News
Markets

CVS Health Corp Stock Bullish Momentum With A 2.99% Rise As Session Comes To An End On Wednesday

ViaNews Editorial Team

December 2, 2020

CVS Health Corp Stock Bullish Momentum With A 2.99% Rise As Session Comes To An End On Wednesday

Shares of CVS Health Corp rose 2.99% to $69.56 at 15:11 EST on Wednesday, after two successive sessions in a row of losses. The New York Stock Exchange is dropping 0.05% to $14,139.30, following yesterday's upward trend, on what up until now seems, a somewhat negative trend trading session today.

CVS Health Corp's last close was $67.54, 9.89% under its 52-week high of $76.44.

CVS Health Corp's Sales

CVS Health Corp's sales growth is 2.6% for the current quarter and 2.3% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 28.9% and a negative 4.7%, respectively.

CVS Health Corp's Revenue

Year-on-year quarterly revenue growth grew by 3.6%, now sitting on 265.28B for the twelve trailing months.

CVS Health Corp's Stock Top and Bottom Yearly Value

CVS Health Corp's stock is valued at $69.56 at 15:11 EST, below its 52-week high of $76.44 and way above its 52-week low of $52.04.

CVS Health Corp's Moving Average

CVS Health Corp's value is higher than its 50-day moving average of $63.35 and way higher than its 200-day moving average of $62.99.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNYSEMarket SessionNYAThe New York Stock ExchangeCVS Health CorpCVSStock Price Up
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com